BC
VRTX icon

Brinker Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Brinker Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$2.26M Sell
7,794
-2,446
-24% -$663K 0.07% 262
2020
Q1 		$2.44M Sell
10,240
-1,684
-14% -$386K 0.1% 210
2019
Q4 		$2.61M Sell
11,924
-554
-4% -$112K 0.08% 243
2019
Q3 		$2.11M Buy
12,478
+11
+0.1% +$1.95K 0.07% 283
2019
Q2 		$2.29M Sell
12,467
-28
-0.2% -$4.89K 0.08% 239
2019
Q1 		$2.3M Sell
12,495
-2,456
-16% -$454K 0.09% 228
2018
Q4 		$2.48M Sell
14,951
-379
-2% -$65.7K 0.11% 180
2018
Q3 		$2.96M Buy
15,330
+162
+1% +$28.8K 0.11% 200
2018
Q2 		$2.58M Buy
15,168
+945
+7% +$146K 0.1% 218
2018
Q1 		$2.32M Buy
14,223
+3,468
+32% +$566K 0.09% 224
2017
Q4 		$1.61M Buy
10,755
+936
+10% +$139K 0.06% 291
2017
Q3 		$1.49M Sell
9,819
-2,413
-20% -$363K 0.06% 297
2017
Q2 		$1.58M Sell
12,232
-1,436
-11% -$173K 0.07% 273
2017
Q1 		$1.5M Buy
13,668
+1,791
+15% +$158K 0.07% 263
2016
Q4 		$875K Buy
11,877
+5,795
+95% +$472K 0.05% 325
2016
Q3 		$530K Sell
6,082
-900
-13% -$85.1K 0.05% 189
2016
Q2 		$601K Buy
6,982
+972
+16% +$84K 0.05% 156
2016
Q1 		$477K Buy
6,010
+2,691
+81% +$243K 0.04% 207
2015
Q4 		$418K Buy
+3,319
New +$401K 0.03% 157
2015
Q3 		– Sell
-10,639
Closed -$1.31M – 141
2015
Q2 		$1.31M Buy
+10,639
New +$1.34M 0.11% 65

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brinker Capital's VRTX Position: Q2 2020 in Review

Brinker Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 24% in Q2 2020, selling an estimated $663K and leaving 7,794 shares worth $2.26M. The position accounts for 0.07% of the portfolio, ranked #262.

Brinker Capital first reported a position in VRTX in Q2 2015 and has held it in 20 quarters since. The position peaked at $2.96M in Q3 2018. 964 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • Brinker Capital held 7,794 shares of Vertex Pharmaceuticals worth $2.26M as of Q2 2020.
  • Brinker Capital sold 2,446 Vertex Pharmaceuticals shares in Q2 2020, an estimated $663K.
  • Vertex Pharmaceuticals made up 0.07% of Brinker Capital's portfolio in Q2 2020, its #262 holding.
  • Brinker Capital first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 20 quarters since.
  • Brinker Capital's Vertex Pharmaceuticals position peaked at $2.96M in Q3 2018.
  • 964 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.